268 related articles for article (PubMed ID: 19270265)
1. HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165.
Lambert S; Bouttier M; Vassy R; Seigneuret M; Petrow-Sadowski C; Janvier S; Heveker N; Ruscetti FW; Perret G; Jones KS; Pique C
Blood; 2009 May; 113(21):5176-85. PubMed ID: 19270265
[TBL] [Abstract][Full Text] [Related]
2. The receptor complex associated with human T-cell lymphotropic virus type 3 (HTLV-3) Env-mediated binding and entry is distinct from, but overlaps with, the receptor complexes of HTLV-1 and HTLV-2.
Jones KS; Huang YK; Chevalier SA; Afonso PV; Petrow-Sadowski C; Bertolette DC; Gessain A; Ruscetti FW; Mahieux R
J Virol; 2009 May; 83(10):5244-55. PubMed ID: 19279090
[TBL] [Abstract][Full Text] [Related]
3. Molecular aspects of HTLV-1 entry: functional domains of the HTLV-1 surface subunit (SU) and their relationships to the entry receptors.
Jones KS; Lambert S; Bouttier M; Bénit L; Ruscetti FW; Hermine O; Pique C
Viruses; 2011 Jun; 3(6):794-810. PubMed ID: 21994754
[TBL] [Abstract][Full Text] [Related]
4. DC-SIGN mediates cell-free infection and transmission of human T-cell lymphotropic virus type 1 by dendritic cells.
Jain P; Manuel SL; Khan ZK; Ahuja J; Quann K; Wigdahl B
J Virol; 2009 Nov; 83(21):10908-21. PubMed ID: 19692463
[TBL] [Abstract][Full Text] [Related]
5. Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells.
Jones KS; Fugo K; Petrow-Sadowski C; Huang Y; Bertolette DC; Lisinski I; Cushman SW; Jacobson S; Ruscetti FW
J Virol; 2006 Sep; 80(17):8291-302. PubMed ID: 16912281
[TBL] [Abstract][Full Text] [Related]
6. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans.
Piñon JD; Klasse PJ; Jassal SR; Welson S; Weber J; Brighty DW; Sattentau QJ
J Virol; 2003 Sep; 77(18):9922-30. PubMed ID: 12941902
[TBL] [Abstract][Full Text] [Related]
7. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry.
Ghez D; Lepelletier Y; Lambert S; Fourneau JM; Blot V; Janvier S; Arnulf B; van Endert PM; Heveker N; Pique C; Hermine O
J Virol; 2006 Jul; 80(14):6844-54. PubMed ID: 16809290
[TBL] [Abstract][Full Text] [Related]
8. Current concepts regarding the HTLV-1 receptor complex.
Ghez D; Lepelletier Y; Jones KS; Pique C; Hermine O
Retrovirology; 2010 Nov; 7():99. PubMed ID: 21114861
[TBL] [Abstract][Full Text] [Related]
9. The N93D mutation of the human T-cell leukemia virus type 1 envelope glycoprotein found in symptomatic patients enhances neuropilin-1 b1 domain binding.
Kusunoki H; Tanaka T; Ohshima C; Sakamoto T; Wakamatsu K; Hamaguchi I
Biochim Biophys Acta Proteins Proteom; 2021 Nov; 1869(11):140708. PubMed ID: 34343702
[TBL] [Abstract][Full Text] [Related]
10. Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells.
Jones KS; Petrow-Sadowski C; Bertolette DC; Huang Y; Ruscetti FW
J Virol; 2005 Oct; 79(20):12692-702. PubMed ID: 16188972
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Binding of Vascular Endothelial Growth Factor-A and Its Receptors to Heparin Selectively Modulates Complex Affinity.
Teran M; Nugent MA
J Biol Chem; 2015 Jun; 290(26):16451-62. PubMed ID: 25979342
[TBL] [Abstract][Full Text] [Related]
12. A novel neuropilin-1-binding sequence in the human T-cell lymphotropic virus type 1 envelope glycoprotein.
Kusunoki H; Tanaka T; Kohno T; Matsuhashi K; Hosoda K; Wakamatsu K; Hamaguchi I
Biochim Biophys Acta Proteins Proteom; 2018 Apr; 1866(4):541-548. PubMed ID: 29458191
[TBL] [Abstract][Full Text] [Related]
13. Interaction between the HTLV-1 envelope and cellular proteins: impact on virus infection and restriction.
Ilinskaya A; Heidecker G; Jones K
Future Med Chem; 2010 Nov; 2(11):1651-68. PubMed ID: 21428837
[TBL] [Abstract][Full Text] [Related]
14. Entry of human T-cell leukemia virus type 1 is augmented by heparin sulfate proteoglycans bearing short heparin-like structures.
Tanaka A; Jinno-Oue A; Shimizu N; Hoque A; Mori T; Islam S; Nakatani Y; Shinagawa M; Hoshino H
J Virol; 2012 Mar; 86(6):2959-69. PubMed ID: 22238310
[TBL] [Abstract][Full Text] [Related]
15. Cellular Factors Involved in HTLV-1 Entry and Pathogenicit.
Hoshino H
Front Microbiol; 2012; 3():222. PubMed ID: 22737146
[TBL] [Abstract][Full Text] [Related]
16. Soluble recombinant HTLV-1 surface glycoprotein competitively inhibits syncytia formation and viral infection of cells.
Jassal SR; Lairmore MD; Leigh-Brown AJ; Brighty DW
Virus Res; 2001 Oct; 78(1-2):17-34. PubMed ID: 11520577
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process.
Kuo CW; Mirsaliotis A; Brighty DW
J Immunol; 2011 Jul; 187(1):361-71. PubMed ID: 21646298
[TBL] [Abstract][Full Text] [Related]
18. Human T-cell leukemia virus type 1 receptor expression among syncytium-resistant cell lines revealed by a novel surface glycoprotein-immunoadhesin.
Jassal SR; Pöhler RG; Brighty DW
J Virol; 2001 Sep; 75(17):8317-28. PubMed ID: 11483777
[TBL] [Abstract][Full Text] [Related]
19. Alternate receptor usage of neuropilin-1 and glucose transporter protein 1 by the human T cell leukemia virus type 1.
Jin Q; Alkhatib B; Cornetta K; Alkhatib G
Virology; 2010 Jan; 396(2):203-12. PubMed ID: 19913864
[TBL] [Abstract][Full Text] [Related]
20. Safety of intraocular anti-VEGF antibody treatment under
Zong Y; Kamoi K; Kurozumi-Karube H; Zhang J; Yang M; Ohno-Matsui K
Front Immunol; 2022; 13():1089286. PubMed ID: 36761168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
